Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Gold, Ralf, Comi, Giancarlo, Palace, Jacqueline, Siever, Arno, Gottschalk, Rebecca, Bijarnia, Mahendra, von Rosenstiel, Philipp, Tomic, Davorka, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915082/
https://www.ncbi.nlm.nih.gov/pubmed/24221641
http://dx.doi.org/10.1007/s00415-013-7115-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915082/
https://www.ncbi.nlm.nih.gov/pubmed/24221641
http://dx.doi.org/10.1007/s00415-013-7115-8

Ejemplares similares